{
  "query": "How effective is pembrolizumab for lung cancer?",
  "response": "For non-small cell lung cancer (NSCLC), pembrolizumab shows approximately 45-55% response rate in patients with high PD-L1 expression (â‰¥50%). The KEYNOTE-024 trial demonstrated superior overall survival compared to chemotherapy.",
  "attention": {
    "sources": [
      "KEYNOTE-024-trial.pdf",
      "JCO-lung-cancer-2017.pdf"
    ],
    "weights": [
      0.7,
      0.3
    ],
    "patterns": [
      "sources:2",
      "outcome:success"
    ]
  },
  "outcome": "success",
  "confidence": 0.89,
  "timestamp": 1760058208794,
  "memory_type": "long-term",
  "id": "896ef6753eff312668206ff6afa7dd0c4c00065a197c29280ce2a9c236bee083"
}